Evidence map›Paper›PMID 28439777›Full record

ReviewJournal of neuro-oncology2017

Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.

Michael G Brandel, Ali A Alattar, Brian R Hirshman, Xuezhi Dong, Kate T Carroll, Mir Amaan Ali, Bob S Carter, Clark C Chen

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07243470 (A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07243470 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors

TypeinterventionalSponsorCentre Leon BerardRan2025 to 2030Enrolled70ConditionsGlioma, CNS Tumor, Adult, CNS Tumor, ChildhoodArmsTarlatamab, Temozolomide (TMZ)
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Misclassification of Diffuse Gliomas: Rates and Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution.

Michael G BrandelDivision of Neurosurgery, Center for Theoretical and Applied Neuro-Oncology, Moores Cancer Center, University of California, 3855 Health Science Drive #0987, La Jolla, San Diego, CA, 92093-0987, USA.
Ali A AlattarDivision of Neurosurgery, Center for Theoretical and Applied Neuro-Oncology, Moores Cancer Center, University of California, 3855 Health Science Drive #0987, La Jolla, San Diego, CA, 92093-0987, USA.
Brian R HirshmanDivision of Neurosurgery, Center for Theoretical and Applied Neuro-Oncology, Moores Cancer Center, University of California, 3855 Health Science Drive #0987, La Jolla, San Diego, CA, 92093-0987, USA.
Xuezhi DongDivision of Neurosurgery, Center for Theoretical and Applied Neuro-Oncology, Moores Cancer Center, University of California, 3855 Health Science Drive #0987, La Jolla, San Diego, CA, 92093-0987, USA.
Kate T CarrollDivision of Neurosurgery, Center for Theoretical and Applied Neuro-Oncology, Moores Cancer Center, University of California, 3855 Health Science Drive #0987, La Jolla, San Diego, CA, 92093-0987, USA.
Mir Amaan AliDivision of Neurosurgery, Center for Theoretical and Applied Neuro-Oncology, Moores Cancer Center, University of California, 3855 Health Science Drive #0987, La Jolla, San Diego, CA, 92093-0987, USA.
Bob S CarterDivision of Neurosurgery, Center for Theoretical and Applied Neuro-Oncology, Moores Cancer Center, University of California, 3855 Health Science Drive #0987, La Jolla, San Diego, CA, 92093-0987, USA.
Clark C ChenDivision of Neurosurgery, Center for Theoretical and Applied Neuro-Oncology, Moores Cancer Center, University of California, 3855 Health Science Drive #0987, La Jolla, San Diego, CA, 92093-0987, USA. clarkchen@ucsd.edu.
Moores Cancer Center

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is limited information on the management strategies and survival trends for oligodendroglioma patients. Here we used the Surveillance, Epidemiology and End Results (SEER, 1999-2012) database to analyze the historical trends of oligodendroglioma patient survival and correlate these trends to evolving clinical practice of radiation therapy (RT) use and surgical practice of gross total resection (GTR). We identified 2689 World Health Organization (WHO) grade II oligodendroglioma (abbreviated as O2) and 1191 WHO grade III oligodendroglioma (abbreviated as O3). Time-trend analyses were performed for overall survival, radiation treatment (RT) use, and extent of surgical resection (EOR). In multivariable Cox models that accounted for age, race, sex, tumor size, tumor location, EOR, and RT status, the hazard of dying from O3 has significantly decreased over the study period (p  <  0.01), while the hazard of dying from O2 has remained largely unchanged. A search of the published literature revealed articles reporting results largely supportive of these observations. The pattern of surgical practice and RT for O3 patients remained unchanged throughout the study period, suggesting that the survival improvement may be related to evolving patterns of medical management. Results from the SEER database indicate significant gains have been made in survival for O3 patients between 1999 and 2012. Such gains were not observed for O2 patients during this study period.

Indexed as

AdolescentAdultAgedBrain NeoplasmsFemaleHumansKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedMultivariate AnalysisNeurosurgical ProceduresOligodendrogliomaProportional Hazards ModelsRadiotherapySEER ProgramOligodendrogliomaPractice patternSEER databaseSurvivalTrends

Identifiers

PMID28439777
OpenAlexW2608303487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.